Christian Goessa, Christopher M. Harris, Sara Murdock, Richard W. McCarthy, Erik Sampson, Rachel Twomey, Suzanne Mathieu, Regina Mario, Matthew Perham, Eric R. Goedken and Andrew J. Long (2018) ABBV-105, a selective and irreversible inhibitor of Bruton’s tyrosine kinase, is efficacious in multiple preclinical models of inflammation, Modern Rheumatology.
https://doi.org/10.1080/14397595.2018.1484269
When the above article was first published online there were errors in the affiliation details for Erik Sampson. At the time the research was conducted Erik Sampson was employed by AbbVie Bioresearch Center, Worcester, MA, USA and not Pandion Therapeutics, Lab Central, Cambridge, MA, USA
The affiliation information has been corrected in both the online and print versions.
Taylor & Francis apologises for this error.